Advertisement

Science China Life Sciences

, Volume 58, Issue 1, pp 101–107 | Cite as

Calcium dobesilate for diabetic retinopathy: a systematic review and meta-analysis

  • XinYuan Zhang
  • Wei Liu
  • ShanShan Wu
  • JingLong Jin
  • WeiHong Li
  • NingLi Wang
Open Access
Research Paper

Abstract

Many randomized clinical controlled trials have confirmed the efficacy and safety of calcium dobesilate in treating diabetic retinopathy (DR). This systematic review critically evaluated the evidence that links calcium dobesilate to DR. In this fixed-effects meta-analysis, a total of 221 pertinent English-language articles published between January 1975 and October 2013 were identified. Systematic searches of PUBMED, Springer Link and the Cochrane Clinical Trials Database were conducted using the keywords “diabetic retinopathy” and “calcium dobesilate”. The extracted information included the study design, inclusion and exclusion criteria, setting, sample size, participant mean age, treatment regime, mean change in best corrected visual acuity, laboratory parameters, capillary fragility, intraocular pressure and fundus manifestations based on the findings of fluorescent angiography. The summary statistics indicated that calcium dobesilate was significantly associated with improving retinal microaneurysms (RR: 0.62, 95%CI: 0.42–0.90, P=0.01), retinalhemorrhages (RR: 0.39, 95% CI: 0.17–0.88, P=0.02); exudates (RR: 0.31, 95% CI: 0.12–0.81, P=0.02), reduction of whole blood viscosity (MD: −0.57 CP, 95% CI: −0.75 to −0.38, P<0.001), plasma viscosity (MD: −0.36 CP, 95% CI: −0.63 to −0.09, P=0.01) and blood cholesterol (MD: −0.48 mg mL−1, 95% CI: −0.64−0.33, P<0.00001). Intraocular pressure was also significantly reduced (MD: −5.59 mmHg, 95% CI: −6.69 to −4.50, P<0.00001). The results indicate that calcium dobesilate effectively treats DR at the systematic and local ocular levels.

Keywords

diabetic retinopathy calcium dobesilate randomized controlled clinical trial systemic review meta- analysis 

References

  1. 1.
    Blindness caused by diabetes—Massachusetts, 1987–1994. MMWR Morb Mortal Wkly Rep, 1996, 45: 937–941Google Scholar
  2. 2.
    Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, Haffner S, Hamman RF, Ikram MK, Kayama T, Klein BE, Klein R, Krishnaiah S, Mayurasakorn K, O’Hare JP, Orchard TJ, Porta M, Rema M, Roy MS, Sharma T, Shaw J, Taylor H, Tielsch JM, Varma R, Wang JJ, Wang N, West S, Xu L, Yasuda M, Zhang X, Mitchell P, Wong TY; Meta- Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care, 2012, 35: 556–564PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Xie X, Xu L, Yang H, Wang S, Jonas JB. Frequency of diabetic retinopathy in the adult population in China: the Beijing Eye Study 2001. Int Ophthalmol, 2009, 29: 485–493PubMedCrossRefGoogle Scholar
  4. 4.
    Xu J, Wei WB, Yuan MX, Yuan SY, Wan G, Zheng YY, Li YB, Wang S, Xu L, Fu HJ, Zhu LX, Pu XL, Zhang JD, Du XP, Li YL, Ji Y, Gu XN, Li Y, Pan SF, Cui XL, Bai W, Chen YJ, Wang ZM, Zhu QS, Gao Y, Liu de Y, Ji YT, Yang Z, Jonas JB. Prevalence and risk factors for diabetic retinopathy: the Beijing Communities Diabetes Study 6. Retina, 2012, 32: 322–329PubMedCrossRefGoogle Scholar
  5. 5.
    Wang FH, Liang YB, Zhang F, Wang JJ, Wei WB, Tao QS, Sun LP, Friedman DS, Wang NL, Wong TY. Prevalence of diabetic retinopathy in rural China: the Handan Eye Study. Ophthalmology, 2009, 116: 461–467PubMedCrossRefGoogle Scholar
  6. 6.
    ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med, 2010, 363: 233–244CrossRefGoogle Scholar
  7. 7.
    Vekasi J, Koltai K, Gaal V, Toth A, Juricskay I, Kesmarky G. The effect of aspirin on hemorheological parameters of patients with diabetic retinopathy. Clin Hemorheol Microcirc, 2008, 39: 385–389PubMedGoogle Scholar
  8. 8.
    Aiello LP, Vignati L, Sheetz MJ, Zhi X, Girach A, Davis MD, Wolka AM, Shahri N, Milton RC. Oral protein kinase c beta inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C beta Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C beta Inhibitor-Diabetic Retinopathy Study 2. Retina, 2011, 31: 2084–2094PubMedCrossRefGoogle Scholar
  9. 9.
    Wilkinson-Berka JL, Rana I, Armani R, Agrotis A. Reactive oxygen species, Nox and angiotensin II in angiogenesis: implications for retinopathy. Clin Sci (Lond), 2013, 124: 597–615CrossRefGoogle Scholar
  10. 10.
    Tillin T, Orchard T, Malm A, Fuller J, Chaturvedi N. The role of antihypertensive therapy in reducing vascular complications of type 2 diabetes. Findings from the DIabetic REtinopathy Candesartan Trials-Protect 2 study. J Hypertens, 2011, 29: 1457–1462PubMedCrossRefGoogle Scholar
  11. 11.
    Ribeiro ML, Caillon P, Gamba G, Cunha-Vaz J, group DX-rs. Efficacy of calcium dobesilate (Doxium(R)) on the blood-retinal barrier permeability in early diabetic retinopathy: a double-blind study. Invest Ophthalmol Vis Sci, 2004, 45: 4153–B614Google Scholar
  12. 12.
    Akbulut B. Calcium dobesilate and oxerutin: effectiveness of combination therapy. Phlebology, 1258, 25: 66–71Google Scholar
  13. 13.
    Ruiz E, Lorente R, Tejerina T. Effects of calcium dobesilate on the synthesis of endothelium-dependent relaxing factors in rabbit isolated aorta. Br J Pharmacol, 1997, 121: 711–716PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Graber R, Farine JC, Losa GA. Calcium Dobesilate protects human peripheral blood mononuclear cells from oxidation and apoptosis. Apoptosis, 1998, 3: 41–49PubMedCrossRefGoogle Scholar
  15. 15.
    Szabo ME, Haines D, Garay E, Chiavaroli C, Farine JC, Hannaert P, Berta A, Garay RP. Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina. Eur J Pharmacol, 2001, 428: 277–286PubMedCrossRefGoogle Scholar
  16. 16.
    Opreanu M, Lydic TA, Reid GE, McSorley KM, Esselman WJ, Busik JV. Inhibition of cytokine signaling in human retinal endothelial cells through downregulation of sphingomyelinases by docosahexaenoic acid. Invest Ophthalmol Vis Sci, 1167, 51: 3253–3263Google Scholar
  17. 17.
    Leal EC, Martins J, Voabil P, Liberal J, Chiavaroli C, Bauer J, Cunha-Vaz J, Ambrosio AF. Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes. Diabetes, 2010, 59: 2637–2645PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17: 1–12PubMedCrossRefGoogle Scholar
  19. 19.
    Larsen HW, Sander E, Hoppe R. The value of calcium dobesilate in the treatment of diabetic retinopathy. A controlled clinical trial. Diabetologia, 1977, 13: 105–109PubMedCrossRefGoogle Scholar
  20. 20.
    Vojnikovic B. Doxium (calcium dobesilate) reduces blood hyperviscosity and lowers elevated intraocular pressure in patients with diabetic retinopathy and glaucoma. Ophthalmic Res, 1991, 23: 12–20PubMedCrossRefGoogle Scholar
  21. 21.
    Leite EB, Mota MC, de Abreu JR, Cunha-Vaz JG. Effect of calcium dobesilate on the blood-retinal barrier in early diabetic retinopathy. Int Ophthalmol, 1990, 14: 81–88PubMedCrossRefGoogle Scholar
  22. 22.
    Benarroch IS, de Salama Benarroch AR, Nano H, Perez H, Bisceglia H. Calcium dobesilate as a treatment for capillary fragility in diabetic retinopathy. Ophthalmologica, 1977, 174: 47–51CrossRefGoogle Scholar
  23. 23.
    Benarroch IS, Brodsky M, Rubinstein A, Viggiano C, Salama EA. Treatment of blood hyperviscosity with calcium dobesilate in patients with diabetic retinopathy. Ophthalmic Res, 1985, 17: 131–138PubMedCrossRefGoogle Scholar
  24. 24.
    Vojnikovic B. Hyperviscosity in whole blood, plasma, and aqueous humor decreased by doxium (calcuim dobesilate) in diabetics with retinopathy and glaucoma: a double-blind controlled study. Ophthalmic Res, 1984, 16: 150–162PubMedCrossRefGoogle Scholar
  25. 25.
    Ribeiro ML, Seres AI, Carneiro AM, Stur M, Zourdani A, Caillon P, Cunha-Vaz JG. Effect of calcium dobesilate on progression of early diabetic retinopathy: a randomised double-blind study. Graefes Arch Clin Exp Ophthalmol, 2006, 244: 1591–1600PubMedCrossRefGoogle Scholar
  26. 26.
    Javadzadeh A, Ghorbanihaghjo A, Adl FH, Andalib D, Khojasteh-Jafari H, Ghabili K. Calcium dobesilate reduces endothelin-1 and high-sensitivity C-reactive protein serum levels in patients with diabetic retinopathy. Mol Vis, 2013, 19: 62–68PubMedPubMedCentralGoogle Scholar
  27. 27.
    Sander B, Thornit DN, Colmorn L, Strom C, Girach A, Hubbard LD, Lund-Andersen H, Larsen M. Progression of diabetic macular edema: correlation with blood retinal barrier permeability, retinal thickness, and retinal vessel diameter. Invest Ophthalmol Vis Sci, 2007, 48: 3983–3987PubMedCrossRefGoogle Scholar
  28. 28.
    Benarroch IS, de Salama Benarroch AR, Nano H, Perez H, Bisceglia H. Calcium dobesilate as a treatment for capillary fragility in diabetic retinopathy. Ophthalmologica, 1974, 168: 370–375PubMedCrossRefGoogle Scholar
  29. 29.
    Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes, 2008, 57: 1026–1033PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Leske MC, Wu SY, Hennis A, Hyman L, Nemesure B, Yang L, Schachat AP. Hyperglycemia, blood pressure, and the 9-year incidence of diabetic retinopathy: the Barbados Eye Studies. Ophthalmology, 2005, 112: 799–805PubMedCrossRefGoogle Scholar
  31. 31.
    Varma R, Macias GL, Torres M, Klein R, Pena FY, Azen SP. Biologic risk factors associated with diabetic retinopathy: the Los Angeles Latino Eye Study. Ophthalmology, 2007, 114: 1332–1340PubMedCrossRefGoogle Scholar
  32. 32.
    Benarous R, Sasongko MB, Qureshi S, Fenwick E, Dirani M, Wong TY, Lamoureux EL. Differential association of serum lipids with diabetic retinopathy and diabetic macular edema. Invest Ophthalmol Vis Sci, 1167, 52: 7464–7469Google Scholar
  33. 33.
    Agroiya P, Philip R, Saran S, Gutch M, Tyagi R, Gupta KK. Association of serum lipids with diabetic retinopathy in type 2 diabetes. Indian J Endocrinol Metab, 2013, 17: S335–337PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Landmesser U, Hornig B, Drexler H. Endothelial dysfunction in hypercholesterolemia: mechanisms, pathophysiological importance, and therapeutic interventions. Semin Thromb Hemost, 2000, 26: 529–537PubMedCrossRefGoogle Scholar
  35. 35.
    Schulz KF, Grimes DA. Generation of allocation sequences in randomised trials: chance, not choice. Lancet, 2002, 359: 515–519PubMedCrossRefGoogle Scholar
  36. 36.
    Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials unnecessary? Picking signal from noise. BMJ, 2007, 334: 349–351PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is “quality of evidence” and why is it important to clinicians? BMJ, 2008, 336: 995–998PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Charles P, Giraudeau B, Dechartres A, Baron G, Ravaud P. Reporting of sample size calculation in randomised controlled trials: review. BMJ, 2009, 338: b1732PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© The Author(s) 2014

Authors and Affiliations

  • XinYuan Zhang
    • 1
  • Wei Liu
    • 1
    • 2
  • ShanShan Wu
    • 3
  • JingLong Jin
    • 4
  • WeiHong Li
    • 4
  • NingLi Wang
    • 1
  1. 1.Beijing Institute of Ophthalmology, Tongren Eye Centre, Tongren HospitalCapital Medical UniversityBeijingChina
  2. 2.University of Science and Technology BeijingBeijingChina
  3. 3.Department of medical resources, Beijing Tongren HospitalCapital Medical UniversityBeijingChina
  4. 4.Department of Epidemiology and Bio-statisticsPeking University Health Science CenterBeijingChina

Personalised recommendations